Therapeutic advances in myositis

Current Opinion in Rheumatology

Volumn 24, Issue 6, 2012, Pages 635-641

  Aggarwal, Rohit ^a   Oddis, Chester V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

dermatomyositis; polymyositis; treatment advances

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CORTICOTROPIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; ECULIZUMAB; ETANERCEPT; FINGOLIMOD; IMMUNOGLOBULIN; INFLIXIMAB; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; LEUKAPHERESIS; MYOSITIS; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW;

AZATHIOPRINE; CYCLOSPORINE; DERMATOMYOSITIS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MYCOPHENOLIC ACID; POLYMYOSITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS;

EID: 84866993536     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328358ac72     Document Type: Review

References (81)

1. Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in polymyositis/dermatomyositis. Adv Exp Med Biol 1999; 455:349-357. (Pubitemid 32187485)
2. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94: 379-387. (Pubitemid 23106624)
3. Miller J, Walsh Y, Saminaden S. Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002; 199:S53.
4. Vencovsky J, Jarosova K, Machacek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29:95-102. (Pubitemid 30434151)
5. Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment: best practice & research. Clin Rheumatol 2009; 23:665-678.
6. Hasija R, Pistorio A, Ravelli A, et al. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum 2011; 63:3142-3152.
7. Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res 2010; 62:219-225.
8. Schiopu E, Phillips K, Macdonald PM, et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 2012; 14:R22.
9. Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41:392-399. (Pubitemid 28128762)
10. Yu KH, Wu YJ, Kuo CF, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 2011; 30:1595-1601.
11. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38:383-392. (Pubitemid 41358669)
12. Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-h postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 2008; 35:254-259. (Pubitemid 351284439)
13. Ingegnoli F, Lubatti C, Ingegnoli A, et al. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 2012; 11:335-340.
14. Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 2011; 30:1021-1028.
15. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetaseassociated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52:2439-2446. (Pubitemid 41117430)
16. Mitsui T, Kuroda Y, Ueno S, Kaji R. The effects of FK506 on refractory inflammatory myopathies. Acta neurologica Belgica 2011; 111:188-194.
17. Ando M, Miyazaki E, Yamasue M et al. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 2010; 29:443-445.
18. Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48:712-716. (Pubitemid 27120112)
19. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002; 46:467-474. (Pubitemid 34136585)
20. Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002; 61:37-41. (Pubitemid 34074837)
21. Manlhiot C, Tyrrell PN, Liang L, et al. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics 2008; 121:e626-e630.
22. Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis 2011; 70:2089-2094.
23. Kampylafka EI, Kosmidis ML, Panagiotakos DB, et al. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol 2012; 30:397-401.
24. Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/ dermatomyositis. Lung 2009; 187:201-206.
25. Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroidrefractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res 2010; 62:1748-1755.
26. Diot E, Carmier D, Marquette D, et al. IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis. Chest 2011; 140:562-563.
27. Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 2011; 139:441-443.
28. Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011; 10:144-149.
29. Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006; 66:1245-1247. (Pubitemid 43739712)
30. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005; 44:386-389. (Pubitemid 40361299)
31. Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007; 46:516-518. (Pubitemid 46344667)
32. Danieli MG, Calcabrini L, Calabrese V, et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 2009; 9:124-127.
33. Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006; 142:65-69. (Pubitemid 43107363)
34. Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62:1496-1501.
35. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009; 337:329-335.
36. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130:30-36. (Pubitemid 44116838)
37. Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62:1446-1451.
38. Dagher R, Desjonqueres M, Duquesne A, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 2012; 32:711-716.
39. Waldman MA, Callen JP. Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. J Am Acad Dermatol 2004; 51:S124-S130.
40. Rios Fernandez R, Callejas Rubio JL, Sanchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27:1009-1016.
41. Valiyil R, Casciola-Rosen L, Hong G et al. Rituximab therapy for myopathy associated with antisignal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62:1328-1334.
42. Deligny C, Goeb V, Dueymes M et al. Rituximab therapy for myopathy associated withanti-signal recognition particle antibodies: a case series. Comment on the article by Valiyil et al. Arthritis Care Res (Hoboken) 2011; 63:460.
43. Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford) 2009; 48:594-595.
44. Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006; 16:334-336.
45. Mahler EA, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology 2011; 50:2206-2213.
46. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007; 143:763-767. (Pubitemid 46955736)
47. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52:601-607. (Pubitemid 40216325)
48. Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007; 56:3107-3111. (Pubitemid 47502758)
49. Chiu YE, Co DO. Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatric Dermatol 2011; 28:357-367.
50. Oddis CV, Reed AM, Aggarwal R. Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM): the RIM study. Arthritis Res 2010; 62:3844.
51. Efthimiou P. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthritis Rheum 2006; 36:168-172. (Pubitemid 44691885)
52. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006; 65:1233-1236. (Pubitemid 44277404)
53. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67:1670-1677.
54. Coyle K, Pokrovnichka A, French K. A randomized double blind placebo controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Res 2008; 58:S293.
55. Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNFalpha in dermato-and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59:159-163. (Pubitemid 351301260)
56. Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006; 33:1802-1804. (Pubitemid 44373214)
57. Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011; 70:427-436.
58. Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 2010; 29:563-566.
59. Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitorassociated dermatomyositis. Arch Dermatol 2010; 146:780-784.
60. Riolo G, Towheed TE. Antitumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol 2012; 39:192-194.
61. Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010; 37:1549-1550.
62. Okada M, Kitahara M, Kishimoto S, et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141:1543-1549.
63. Gabay C, Gay-Croisier F, Roux-Lombard P, et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994; 37:1744-1751. (Pubitemid 24371875)
64. Lundberg I, Ulfgren AK, Nyberg P, et al. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40:865-874. (Pubitemid 27200003)
65. Lepidi H, Frances V, Figarella-Branger D, et al. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998; 24:73-79. (Pubitemid 28105417)
66. Scuderi F, Mannella F, Marino M, et al. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol 2006; 176:9-15. (Pubitemid 44080332)
67. Okiyama N, Sugihara T, Iwakura Y, et al. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 2009; 60:2505-2512.
68. Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology 2011; 50:1344-1346.
69. Catania A, Lonati C, Sordi A, et al. The melanocortin system in control of inflammation. ScientificWorldJournal 2010; 10:1840-1853.
70. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004; 56:1-29. (Pubitemid 38314578)
71. Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996; 97:375-379. (Pubitemid 26076265)
72. Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther 2011; 5:147-153.
73. Simsarian JP, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial. Drug Des Devel Ther 2011; 5:381-389.
74. Levine TD. Treating refractory dermatomyosits or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther 2012; 6:133-139.
75. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326:1380-1384.
76. Pons-Estel GJ, Salerni GE, Serrano RM, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev 2011; 10:679-684.
77. Kazuki T, Bookbinder S, Furie R. A pilot study of eculizumab in patients with dermatomyositis. Arthritis Res 2002; 46:S489.
78. Thompson B, Corris P, Miller JA, et al. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 2008; 35:2080-2082.
79. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132:1536-1544.
80. Greenberg SA, Higgs BW, Morehouse C, et al. Relationship between disease activity and type 1 interferon-and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 2012; 13:207-213.
81. Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 2011; 13:249. The overexpression of Type 1 IFN-inducible genes in active myositis patients.